Daily Respiratory Research Analysis
Analyzed 165 papers and selected 3 impactful papers.
Summary
Analyzed 165 papers and selected 3 impactful articles.
Selected Articles
1. Plasma proteomic signatures of cellular aging predict human disease.
Using >7,000 plasma proteins in 60,542 individuals, the authors built machine-learning models to estimate biological aging across >40 cell types. Cell-type aging signatures predicted incident disease and mortality, and in smokers, extreme aging of respiratory epithelial cells increased lung cancer risk by 58%. A polycellular aging risk score stratified mortality across cohorts and platforms.
Impact: This study introduces a scalable, noninvasive proteomic framework to quantify cell-type-specific aging that robustly predicts disease and mortality, with direct implications for respiratory cancer risk stratification.
Clinical Implications: Proteomic aging signatures could augment risk models for lung cancer (especially in smokers) and guide targeted prevention/screening strategies. Longitudinal monitoring may inform timing of interventions aimed at modulating biological aging.
Key Findings
- Built machine-learning models from >7,000 plasma proteins in 60,542 individuals to estimate biological age for >40 cell types.
- Cell-type aging signatures predicted incident disease and all-cause mortality over up to 15 years.
- In smokers, extreme respiratory epithelial aging conferred a 58% higher lung cancer risk versus smoking alone.
- APOE genotype showed divergent cell-type aging patterns (e.g., older astrocytes in APOE4 carriers) linked to disease risk.
- A polycellular aging risk score stratified mortality risk across cohorts and proteomics platforms.
Methodological Strengths
- Very large, multi-cohort dataset with >60,000 participants and >7,000 proteins enabling robust modeling.
- Longitudinal validation for incident disease and mortality with cross-platform generalizability.
Limitations
- Observational design precludes causal inference; interventions to modify aging signatures were not tested.
- Potential variability across proteomics platforms and cohorts requires further harmonization for clinical deployment.
Future Directions: Prospective clinical studies to integrate proteomic aging signatures into lung cancer screening algorithms, and interventional trials testing whether modifying aging biology reduces incident disease.
Aging is asynchronous across cells and organs. Here we tested whether plasma proteomics can be used to analyze cell type-specific aging. From analyses of over 7,000 plasma proteins measured in 60,542 individuals, we developed machine learning models to estimate the biological age of over 40 cell types spanning neuronal, immune, glial, endocrine, epithelial and musculoskeletal origins. We observed that 20-25% of individuals exhibited accelerated aging in a single cell type and 1-3% in 10 or more cell types. Cellular aging signatures were associated with disease status and predicted incident disease and mortality over 15 years of follow-up.
2. Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial.
In the phase 3 AENEAS2 trial (n=624), first-line aumolertinib plus platinum–pemetrexed significantly prolonged BICR-assessed progression-free survival versus aumolertinib alone (median 28.9 vs 18.9 months; HR 0.47; p<0.0001). Hematologic grade 3–4 adverse events were markedly more frequent with combination therapy, but were manageable with dose modifications and supportive care.
Impact: This rigorously conducted phase 3 RCT demonstrates a clinically meaningful PFS benefit of adding chemotherapy to a third-generation EGFR-TKI, informing first-line treatment strategies in EGFR-mutated NSCLC.
Clinical Implications: For fit patients with EGFR exon 19 deletion or L858R, aumolertinib plus pemetrexed-platinum is a practice-relevant option to delay progression; clinicians must proactively monitor and manage hematologic toxicity and consider patient preferences and comorbidities.
Key Findings
- Median PFS: 28.9 months (combination) vs 18.9 months (monotherapy); HR 0.47 (95% CI 0.37–0.60), p<0.0001.
- Grade 3–4 neutropenia, leukopenia, and thrombocytopenia occurred in 55%, 34%, and 20% with combination vs 1%, <1%, and 1% with monotherapy.
- Serious adverse events were more frequent with combination (36% vs 17%), with few treatment-related deaths (1 vs 2).
Methodological Strengths
- Multicentre randomized controlled design with stratification and blinded independent central review for PFS.
- Adequate sample size (n=624) with prespecified analyses and clinically relevant endpoints.
Limitations
- Open-label design may introduce assessment or management biases despite BICR for PFS.
- Overall survival and quality-of-life outcomes are immature; generalizability outside a predominantly Chinese cohort requires caution.
Future Directions: Define optimal chemotherapy duration/intensity with third-generation EGFR-TKIs, identify predictive biomarkers for combination benefit, and report mature OS and patient-reported outcomes.
BACKGROUND: Although third-generation epidermal growth-factor receptor (EGFR)-tyrosine-kinase inhibitors (TKIs) are standard first-line therapies for patients with advanced EGFR-mutated non-small-cell lung cancer (NSCLC), their effectiveness is often limited by the emergence of drug resistance and subsequent disease progression. Given the previously established clinical efficacy and adverse event profile of aumolertinib, we aimed to evaluate the efficacy and adverse event profile of aumolertinib in co
3. Paraseptal Emphysema and Interstitial Lung Abnormalities in AGES-Reykjavik Study.
In 5,059 participants, pure paraseptal and mixed emphysema were strongly associated with ILA (adjusted OR ~5), while pure centrilobular emphysema was not. Over 8.3 years, mixed emphysema increased mortality (adjusted HR 1.47), and the presence of ILA elevated mortality in both PSE and CLE groups (HR 1.48 and 1.44).
Impact: This large, longitudinal cohort clarifies that ILA coexisting with emphysema is a consistent mortality signal, supporting routine assessment of ILA in emphysema phenotyping and risk stratification.
Clinical Implications: Radiologists and pulmonologists should systematically assess ILA in patients with paraseptal or mixed emphysema. ILA may identify patients needing closer follow-up, pulmonary rehabilitation, or consideration in antifibrotic trial eligibility.
Key Findings
- Pure paraseptal and mixed emphysema were strongly associated with ILA (adjusted OR 4.99 and 5.07).
- Over 8.3±2.6 years, mixed emphysema increased all-cause mortality (adjusted HR 1.47).
- ILA presence increased mortality among both PSE and CLE participants (adjusted HR 1.48 and 1.44).
- PSE severity was not significantly associated with ILA prevalence or prognosis.
Methodological Strengths
- Large, population-based cohort with standardized visual classification and multivariable adjustment.
- Long follow-up enabling robust mortality assessment.
Limitations
- Observational design leaves potential residual confounding.
- Visual emphysema/ILA scoring may be subject to interobserver variability; quantitative CT metrics were not detailed.
Future Directions: Validate automated quantitative CT metrics for ILA detection in emphysema and test whether ILA-guided management alters outcomes.
BACKGROUND: Paraseptal emphysema (PSE) is often underrecognized because it has minimal impact on pulmonary function. Recent studies suggest its frequent coexistence with interstitial lung abnormalities (ILA) and potential clinical significance, yet population-based data on its prevalence and prognostic impact remain unclear. PURPOSE: To examine the associations between visual emphysema subtypes and ILA, and to evaluate the prognostic impact of ILA in individuals with emphysema subtypes. MATERIALS AND METHODS: We analyzed 5,059 participants from Age Gene/Environment Susceptibility Reykjavik Study. Emphysema was classified as no emphysema, pure PSE, mixed emphysema, or pure centrilobular emphysema (CLE), and ILA as no ILA, indeterminate ILA, or ILA.